Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 4/2015

01-04-2015 | Original paper

Statins and breast cancer stage and mortality in the Women’s Health Initiative

Authors: Pinkal Desai, Amy Lehman, Rowan T. Chlebowski, Marilyn L. Kwan, Monica Arun, JoAnn E. Manson, Sayeh Lavasani, Sylvia Wasswertheil-Smoller, Gloria E. Sarto, Meryl LeBoff, Jane Cauley, Michele Cote, Jennifer Beebe-Dimmer, Allison Jay, Michael S. Simon

Published in: Cancer Causes & Control | Issue 4/2015

Login to get access

Abstract

Purpose

To evaluate the association between statins and breast cancer stage and mortality in the Women’s Health Initiative.

Methods

The study population included 128,675 postmenopausal women aged 50–79 years, out of which there were 7,883 newly diagnosed cases of in situ (19 %), local (61 %)-, regional (19 %)- and distant (1 %)-stage breast cancer and 401 deaths due to breast cancer after an average of 11.5 (SD = 3.7) years of follow-up. Stage was coded using SEER criteria and was stratified into early (in situ and local)- versus late (regional and distant)-stage disease. Information on statins and other risk factors were collected by self- and interviewer-administered questionnaires. Cause of death was based on medical record review. Multivariable-adjusted hazards ratios (HR) and 95 % confidence intervals (CIs) evaluating the relationship between statin use (at baseline only and in a time-dependent manner) and diagnosis of late-stage breast cancer and breast cancer-specific mortality were computed from Cox proportional hazards analyses after adjusting for appropriate confounders.

Results

Statins were used by 10,474 women (8 %) at baseline. In the multivariable-adjusted time-dependent model, use of lipophilic statins was associated with a reduction in diagnosis of late-stage breast cancer (HR 0.80, 95 % CI 0.64–0.98, p = 0.035) which was also significant among women with estrogen receptor-positive disease (HR 0.72, 95 % CI 0.56–0.93, p = 0.012). Breast cancer mortality was marginally lower in statin users compared with nonusers (HR 0.59, 95 % CI 0.32–1.06, p = 0.075).

Conclusions

Prior statin use is associated with lower breast cancer stage at diagnosis.
Literature
1.
2.
Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278CrossRefPubMed
3.
4.
5.
6.
Wachtershauser A, Akoglu B, Stein J (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22(7):1061–1067CrossRefPubMed
7.
Agarwal B, Halmos B, Feoktistov AS et al (2002) Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 23(3):521–528CrossRefPubMed
8.
Spampanato C, De MS, Sarnataro M et al (2012) Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol 40(4):935–941PubMedCentralPubMed
9.
Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS (2008) Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 123(4):951–957CrossRefPubMed
10.
Cauley JA, McTiernan A, Rodabough RJ et al (2006) Statin use and breast cancer: prospective results from the women’s health initiative. J Natl Cancer Inst 98(10):700–707CrossRefPubMed
11.
Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM (2008) Statin use and risk of breast cancer. Cancer 112(1):27–33CrossRefPubMed
12.
Haukka J, Sankila R, Klaukka T et al (2010) Incidence of cancer and statin usage—record linkage study. Int J Cancer 126(1):279–284CrossRefPubMed
13.
Desai P, Chlebowski R, Cauley JA et al (2013) Prospective analysis of association between statin use and breast cancer risk in the women’s health initiative. Cancer Epidemiol Biomarkers Prev 22(10):1868–1876CrossRefPubMedCentralPubMed
14.
Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomark Prev 17(5):1028–1033CrossRef
15.
Chae YK, Valsecchi ME, Kim J et al (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29(9):585–593CrossRefPubMed
16.
Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579CrossRefPubMedCentralPubMed
17.
Ahern TP, Pedersen L, Tarp M et al (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468CrossRefPubMedCentralPubMed
18.
Nickels S, Vrieling A, Seibold P et al (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 8(9):e75088CrossRefPubMedCentralPubMed
19.
Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802CrossRefPubMed
20.
Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group (1998) Control Clin Trials 19(1):61–109
21.
Anderson GL, Manson J, Wallace R et al (2003) Implementation of the women’s health initiative study design. Ann Epidemiol 13(9 Suppl):S5–17CrossRefPubMed
22.
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed
23.
Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19(1):117–125CrossRefPubMed
24.
Fong CW (2014) Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem 85C:661–674CrossRef
25.
Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the women’s health initiative. Ann Epidemiol 13(9 Suppl):S122–S128CrossRefPubMed
26.
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509CrossRef
27.
Holstein SA, Wohlford-Lenane CL, Hohl RJ (2002) Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 41(46):13698–13704CrossRefPubMed
28.
Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14(8):1897–1898CrossRefPubMed
29.
Seasholtz TM, Majumdar M, Brown JH (1999) Rho as a mediator of G protein-coupled receptor signaling. Mol Pharmacol 55(6):949–956PubMed
30.
Denoyelle C, Vasse M, Korner M et al (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8):1139–1148CrossRefPubMed
31.
Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572–1585CrossRefPubMed
32.
Asakage M, Tsuno NH, Kitayama J et al (2004) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs 15(6):625–632CrossRefPubMed
33.
Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51(13):3602–3609PubMed
34.
Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50(1):83–93CrossRefPubMed
35.
Farina HG, Bublik DR, Alonso DF, Gomez DE (2002) Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 19(6):551–559CrossRefPubMed
36.
Cauley JA, Zmuda JM, Lui LY et al (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12(8):749–756CrossRef
37.
Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case–control study. Cancer 100(11):2308–2316CrossRefPubMed
38.
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606–8612CrossRefPubMed
Metadata
Title
Statins and breast cancer stage and mortality in the Women’s Health Initiative
Authors
Pinkal Desai
Amy Lehman
Rowan T. Chlebowski
Marilyn L. Kwan
Monica Arun
JoAnn E. Manson
Sayeh Lavasani
Sylvia Wasswertheil-Smoller
Gloria E. Sarto
Meryl LeBoff
Jane Cauley
Michele Cote
Jennifer Beebe-Dimmer
Allison Jay
Michael S. Simon
Publication date
01-04-2015
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 4/2015
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0530-7

Other articles of this Issue 4/2015

Cancer Causes & Control 4/2015 Go to the issue

Original paper

Plasma lipid levels and colorectal adenoma risk

Letter to the editor

Second primary malignancies in Waldenstrom’s macroglobulinemia: a US population-based study

Original paper

Dietary patterns and endometrial cancer risk in the California Teachers Study cohort

Original paper

Soy isoflavone intake and bone mineral density in breast cancer survivors

Original paper

Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis

Original paper

Association between tobacco use and the upper gastrointestinal microbiome among Chinese men
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits